Home » Stocks » LJPC

La Jolla Pharmaceutical Company (LJPC)

Stock Price: $4.02 USD -0.06 (-1.35%)
Updated Apr 19, 2021 1:41 PM EDT - Market open
Market Cap 111.63M
Revenue (ttm) 33.42M
Net Income (ttm) -39.42M
Shares Out 27.33M
EPS (ttm) -1.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $4.02
Previous Close $4.07
Change ($) -0.06
Change (%) -1.35%
Day's Open 4.02
Day's Range 3.93 - 4.06
Day's Volume 115,711
52-Week Range 3.36 - 8.10

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 62.86% and 7.68%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients sufferin...

1 month ago - Business Wire

La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients sufferin...

3 months ago - Business Wire

La Jolla Pharmaceutical Company (LJPC) has been struggling lately, but the selling pressure may be coming to an end soon.

3 months ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients sufferin...

5 months ago - Business Wire

SAN DIEGO, California, Aug. 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that impr...

8 months ago - GlobeNewsWire

SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that its Board of Directors has appointed Larry Edwards as President and Chief Executive Off...

8 months ago - GlobeNewsWire

-Combined Company Offers Two Innovative Therapies to Treat Patients Suffering from Life-threatening Diseases- -Combined Company Offers Two Innovative Therapies to Treat Patients Suffering from Life-thre...

8 months ago - GlobeNewsWire

La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights

9 months ago - GlobeNewsWire

La Jolla (LJPC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

10 months ago - Zacks Investment Research

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 58.44% and -10.69%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

SAN DIEGO, May 04, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes ...

11 months ago - GlobeNewsWire

La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

SAN DIEGO, April 07, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcome...

1 year ago - GlobeNewsWire

SAN DIEGO, April 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcome...

1 year ago - GlobeNewsWire

SAN DIEGO, April 03, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcome...

1 year ago - GlobeNewsWire

SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcome...

1 year ago - GlobeNewsWire

The following are the latest biotech announcements from late Thursday and Friday morning on the development of products targeting the coronavirus.

Other stocks mentioned: AYTU, CANF, ENTA, LLY, OPK, RHHBY
1 year ago - Benzinga

SAN DIEGO, March 13, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcome...

1 year ago - GlobeNewsWire

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 5.10% and 0.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in La Jolla Pharmaceutical.

1 year ago - Zacks Investment Research

Insider buying can be an encouraging signal for potential investors. Insiders at some small-cap biotechs have made notable share purchases.

Other stocks mentioned: APTX, OSMT
1 year ago - Benzinga

SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to signific...

1 year ago - GlobeNewsWire

Shares of La Jolla Pharmaceutical Company fell 30% in premarket trading after it announced president and CEO George Tidmarsh had left the company and that the company plans to "re-evaluate its current ...

1 year ago - Market Watch

SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to signific...

1 year ago - GlobeNewsWire

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -0.93% and -18.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the st...

1 year ago - Zacks Investment Research

La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

This year, for the first time in many years, active managers are outperforming index funds, and that should be a loud wake-up call to passive investors.

Other stocks mentioned: AXSM, BHC, CHNG, HQY
1 year ago - 24/7 Wall Street

SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to signifi...

1 year ago - GlobeNewsWire

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CDEV, CISN, NOG, VER
1 year ago - 24/7 Wall Street

SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to signific...

1 year ago - GlobeNewsWire

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 0.00% and -1.04%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

The CHMP recommends La Jolla's (LJPC) marketing application for Giapreza to treat refractory hypotension in adult patients with septic or distributive shock.

1 year ago - Zacks Investment Research

La Jolla Pharmaceutical announced positive results from its phase 2 study using LJPC-401 to treat patients with hereditary hemochromatosis.

1 year ago - Seeking Alpha

Successful turnaround stories are like Cinderella bioscience stocks. They do not come around often but the profits from a successful turnaround are phenomenal.

1 year ago - Seeking Alpha

La Jolla Pharmaceutical (LJPC) needs investors to pay close attention to the stock based on moves in the options market lately.

1 year ago - Zacks Investment Research

A mid-stage clinical trial has investors excited about the biotech's future.

1 year ago - The Motley Fool

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 10.69% and -11.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

This off-the radar pick could be poised to be a huge winner. Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company.

Other stocks mentioned: GLMD, INO, MNKD, VKTX
2 years ago - 24/7 Wall Street

About LJPC

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the Unit... [Read more...]

Industry
Biotechnology
IPO Date
Jun 3, 1994
Stock Exchange
NASDAQ
Ticker Symbol
LJPC
Full Company Profile

Financial Performance

In 2020, LJPC's revenue was $33.42 million, an increase of 44.96% compared to the previous year's $23.05 million. Losses were -$39.42 million, -66.16% less than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for LJPC stock is "Buy." The 12-month stock price forecast is 9.33, which is an increase of 132.38% from the latest price.

Price Target
$9.33
(132.38% upside)
Analyst Consensus: Buy